Lorena V Baroni1, Agustina Oller2, Candela S Freytes3, Claudia V Sampor3, Natalia Pinto4, Nicolas Ponce Fernandez3, Carlos Rugilo5, Fabiana Lubieniecki6, Pedro Zubizarreta3, Daniel Alderete7. 1. Service of Hematology/Oncology, Hospital JP Garrahan, 1881 Combate de los Pozos Street, Buenos Aires, Argentina. lorelein@msn.com. 2. Service of Hematology/Oncology, Hospital JP Garrahan, 1881 Combate de los Pozos Street, Buenos Aires, Argentina. agustinaoller@gmail.com. 3. Service of Hematology/Oncology, Hospital JP Garrahan, 1881 Combate de los Pozos Street, Buenos Aires, Argentina. 4. Service of Radiotherapy, Hospital JP Garrahan, Buenos Aires, Argentina. 5. Service of Diagnostic Imaging, Hospital JP Garrahan, Buenos Aires, Argentina. 6. Service of Pathology, Hospital JP Garrahan, Buenos Aires, Argentina. 7. Service of Hematology/Oncology, Hospital JP Garrahan, 1881 Combate de los Pozos Street, Buenos Aires, Argentina. Danalder09@gmail.com.
Abstract
BACKGROUND: Intracranial germ cell tumor (iGCT) represents a rare and heterogeneous group, with variable incidence and diverse treatment strategies. Although multiagent chemotherapy with reduced radiotherapy strategy has been applied by several cooperative groups in North America and Western Europe, there is a paucity of data to understand if this combined regimen is suitable in low-middle income countries (LMIC). METHODS: We evaluate the outcome in a cohort of iGCT treated by SIOP-CNS-GCT-96 strategy at hospital J.P Garrahan in Argentina over the last 20 years. Radiation field and dose included focal radiotherapy (FRT) before 2009 or focal radiotherapy plus whole ventricular radiotherapy (WVRT) after 2009 for localized germinoma and FRT or FRT plus WVRT or CSI for non germinomatous germ cell tumors (NGGCT) RESULTS: Sixty iGCT were identified; 39 germinoma and 21 NGGCT. Median follow-up was 6.57 years (range 0.13-20.5). 5-year PFS and OS were 83.5% (95% CI [165.53-223.2]) and 88.7% (95% CI [169.84-223.2]) for the germinoma group, while for the NGGCT group were 75% (95% CI [133.27-219.96]) and 64.2% (95% CI [107.38-201.81]) respectively. The localized germinoma group showed poor results between 2000 and 2009 with 5-year PFS and OS of 69 and 75% respectively, and an excellent outcome between 2010 and 2019 with a 5-years PFS and OS of 92.8 and 100%. A univariable analysis identified this difference in survival as related to the field of radiotherapy, specifically whole ventricular radiotherapy. FRT increased the risk of recurrence in localized germinoma, involving not only ventricular relapses; but spinal cord and disseminated disease as well. There were no relapses of localized NGGCT after FRT and FRT plus WVRT. CONCLUSION: Herein we demonstrate that intensive chemotherapy followed by FRT plus WVRT for germinoma is a feasible and effective strategy, warranting further study in the developing world.
BACKGROUND: Intracranial germ cell tumor (iGCT) represents a rare and heterogeneous group, with variable incidence and diverse treatment strategies. Although multiagent chemotherapy with reduced radiotherapy strategy has been applied by several cooperative groups in North America and Western Europe, there is a paucity of data to understand if this combined regimen is suitable in low-middle income countries (LMIC). METHODS: We evaluate the outcome in a cohort of iGCT treated by SIOP-CNS-GCT-96 strategy at hospital J.P Garrahan in Argentina over the last 20 years. Radiation field and dose included focal radiotherapy (FRT) before 2009 or focal radiotherapy plus whole ventricular radiotherapy (WVRT) after 2009 for localized germinoma and FRT or FRT plus WVRT or CSI for non germinomatous germ cell tumors (NGGCT) RESULTS: Sixty iGCT were identified; 39 germinoma and 21 NGGCT. Median follow-up was 6.57 years (range 0.13-20.5). 5-year PFS and OS were 83.5% (95% CI [165.53-223.2]) and 88.7% (95% CI [169.84-223.2]) for the germinoma group, while for the NGGCT group were 75% (95% CI [133.27-219.96]) and 64.2% (95% CI [107.38-201.81]) respectively. The localized germinoma group showed poor results between 2000 and 2009 with 5-year PFS and OS of 69 and 75% respectively, and an excellent outcome between 2010 and 2019 with a 5-years PFS and OS of 92.8 and 100%. A univariable analysis identified this difference in survival as related to the field of radiotherapy, specifically whole ventricular radiotherapy. FRT increased the risk of recurrence in localized germinoma, involving not only ventricular relapses; but spinal cord and disseminated disease as well. There were no relapses of localized NGGCT after FRT and FRT plus WVRT. CONCLUSION: Herein we demonstrate that intensive chemotherapy followed by FRT plus WVRT for germinoma is a feasible and effective strategy, warranting further study in the developing world.
Entities:
Keywords:
Brain tumor; Germ-cell tumor; Germinoma; Non germinomatous; Reduced radiation field
Authors: Soumen Khatua; Girish Dhall; Sharon O'Neil; Rima Jubran; Judith G Villablanca; Araz Marachelian; Arti Nastia; Robert Lavey; Arthur J Olch; Ignacio Gonzalez; Floyd Gilles; Marvin Nelson; Ashok Panigrahy; Gordon McComb; Mark Krieger; Jing Fan; Richard Sposto; Jonathan L Finlay Journal: Pediatr Blood Cancer Date: 2010-07-15 Impact factor: 3.167
Authors: Claire Alapetite; Herve Brisse; Catherine Patte; Marie Anne Raquin; Genevieve Gaboriaud; Christian Carrie; Jean Louis Habrand; Philippe Thiesse; Jean Claude Cuilliere; Valerie Bernier; M Ben-Hassel; Didier Frappaz; Marie Christine Baranzelli; Eric Bouffet Journal: Neuro Oncol Date: 2010-08-17 Impact factor: 12.300